Neuspera Medical iSNM to Achieve Medicare Payment Equality with Legacy Devices in 2027 Rule
Neuspera Medical recently announced an important development regarding its Integrated Sacral Neuromodulation System (iSNM), with the Centers for Medicare & Medicaid Services (CMS) confirming that the iSNM will receive the same billing code and payment level as existing implanted sacral neuromodulation (SNM) devices. This decision, outlined in the proposed Outpatient Prospective Payment System rule for Calendar Year 2027, marks a significant step for patient access in the realm of urinary urge incontinence treatments.
The billing code assignment to APC Level 5464 signifies that the iSNM system will be compensated at a payment rate of $22,150 in 2027, which is an increase of 11.8% from the previous year. This adjustment not only fosters equitable treatment access for Medicare beneficiaries but also encourages the uptake of this cutting-edge technology among patients who have previously faced difficulties with conventional SNM systems—primarily those reliant on cumbersome implanted batteries.
David Van Meter, CEO of Neuspera, expressed appreciation for CMS's decision, highlighting that it equalizes the financial landscape for patients needing SNM therapies and protects them from the complications commonly associated with traditional devices. “This move puts us on equal footing and will enable many more patients to benefit from SNM without the issues tied to old systems,” Van Meter stated.
The Neuspera iSNM has attracted attention particularly for its innovative design which eliminates several discomforts related to traditional battery-operated SNM implementations. The legacy systems, while effective, often necessitate invasive surgical interventions, revisiting battery-related issues, and managing complications such as pocket pain and infections. A recent study from the Cleveland Clinic highlighted that a significant percentage of patients experienced substantial discomfort from traditional devices, with 62% reporting the sensation of the device, and even higher rates indicating activity-related discomfort or movement limitations. This highlights a dire need for alternatives like the iSNM.
To further establish its clinical effectiveness, the Neuspera iSNM is undergoing assessments within the FREEDOM registry—a multi-center observational study aimed at capturing quality-of-life improvements, satisfaction levels, and additional outcomes from patients transitioning from conventional systems to the iSNM technology.
The registry aims to validate the advantages of the iSNM system while systematically documenting the patient experience. The study has already showcased promising initial cases, demonstrating that the iSNM can effectively reduce complications and enhance patient satisfaction compared to its legacy counterparts.
Experts have noted that the advantages the Neuspera system presents are monumental. Dr. Charles R. Powell, a notable urologist, commented on its importance, emphasizing how the iSNM addresses longstanding concerns with traditional therapies. It has the potential to convert many individuals who have historically shied away from sacral neuromodulation due to fears about implanted devices into patients that can benefit from this treatment.
Despite the robust efficacy clinically linked to the SNM options—the responder rates for these therapies hovering between 80-90%—market penetration remains notably low, with fewer than 5 in 100 prospective patients opting for this course of treatment. The guidelines set forth by the new CMS adjustments are likely to encourage broader adoption and potentially reshape therapeutic standards within the field.
Neuspera Medical’s innovative approach resonates with an urgent need for improved patient experiences in the realm of urinary incontinence. With this CMS announcement, it is evident that change is on the horizon, paving the way for more effective, patient-friendly solutions that prioritize user experience, safety, and technology-driven healthcare innovations. For further details on the Neuspera iSNM system, stakeholders are encouraged to visit their official website or consult the company’s latest publications regarding the FREEDOM Registry.
The billing code assignment to APC Level 5464 signifies that the iSNM system will be compensated at a payment rate of $22,150 in 2027, which is an increase of 11.8% from the previous year. This adjustment not only fosters equitable treatment access for Medicare beneficiaries but also encourages the uptake of this cutting-edge technology among patients who have previously faced difficulties with conventional SNM systems—primarily those reliant on cumbersome implanted batteries.
David Van Meter, CEO of Neuspera, expressed appreciation for CMS's decision, highlighting that it equalizes the financial landscape for patients needing SNM therapies and protects them from the complications commonly associated with traditional devices. “This move puts us on equal footing and will enable many more patients to benefit from SNM without the issues tied to old systems,” Van Meter stated.
The Neuspera iSNM has attracted attention particularly for its innovative design which eliminates several discomforts related to traditional battery-operated SNM implementations. The legacy systems, while effective, often necessitate invasive surgical interventions, revisiting battery-related issues, and managing complications such as pocket pain and infections. A recent study from the Cleveland Clinic highlighted that a significant percentage of patients experienced substantial discomfort from traditional devices, with 62% reporting the sensation of the device, and even higher rates indicating activity-related discomfort or movement limitations. This highlights a dire need for alternatives like the iSNM.
To further establish its clinical effectiveness, the Neuspera iSNM is undergoing assessments within the FREEDOM registry—a multi-center observational study aimed at capturing quality-of-life improvements, satisfaction levels, and additional outcomes from patients transitioning from conventional systems to the iSNM technology.
The registry aims to validate the advantages of the iSNM system while systematically documenting the patient experience. The study has already showcased promising initial cases, demonstrating that the iSNM can effectively reduce complications and enhance patient satisfaction compared to its legacy counterparts.
Experts have noted that the advantages the Neuspera system presents are monumental. Dr. Charles R. Powell, a notable urologist, commented on its importance, emphasizing how the iSNM addresses longstanding concerns with traditional therapies. It has the potential to convert many individuals who have historically shied away from sacral neuromodulation due to fears about implanted devices into patients that can benefit from this treatment.
Despite the robust efficacy clinically linked to the SNM options—the responder rates for these therapies hovering between 80-90%—market penetration remains notably low, with fewer than 5 in 100 prospective patients opting for this course of treatment. The guidelines set forth by the new CMS adjustments are likely to encourage broader adoption and potentially reshape therapeutic standards within the field.
Neuspera Medical’s innovative approach resonates with an urgent need for improved patient experiences in the realm of urinary incontinence. With this CMS announcement, it is evident that change is on the horizon, paving the way for more effective, patient-friendly solutions that prioritize user experience, safety, and technology-driven healthcare innovations. For further details on the Neuspera iSNM system, stakeholders are encouraged to visit their official website or consult the company’s latest publications regarding the FREEDOM Registry.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.